Skip to content

BHIVA: UK HIV patients remained on first combination for almost seven years during early-HAART era

New treatment for oral thrush as effective as current standard of care, and better at preventing relapse

Final report on 3 by 5 - target not met, but progress and valuable lessons for universal access by 2010

Wide variability in drug levels casts doubt on the practicality of therapeutic drug monitoring

Unexpected interaction between heroin substitute and atazanavir/ritonavir

Rare resistance mutation, K65N, means that multiple NRTIs don't work well

HAART failure rate halves in seven years

Debate continues over interaction between ritonavir-boosted atazanavir and antacids

Family support just as good as directly observed therapy for TB treatment, Nepal study finds